| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/28/2004 | EP0823895B1 Fatty acid esters as bioactive compounds |
| 07/28/2004 | EP0696201B1 Supplemented tissue sealants, methods of their production and use |
| 07/28/2004 | CN1516606A Dry powder inhalation system for transpulmonary administration |
| 07/28/2004 | CN1516601A Orally deliverable pharmaceutical composition comprising drug of low water solubility (cox-2 inhibitor), solvent, fatty acid and organic amine |
| 07/28/2004 | CN1516595A Patch for transcutaneous immunization |
| 07/28/2004 | CN1516593A A topical anti-itchu formulation and process for preparation thereof |
| 07/28/2004 | CN1516591A Preparation of therapeutic composition |
| 07/28/2004 | CN1516588A Combination of brimonidine and timolol for topical ophthalmic use |
| 07/28/2004 | CN1516583A Pharmaceutical compositions comprising chelidonine or derivatives thereof |
| 07/28/2004 | CN1516581A Amino-sulfonyl-containing active compound (COX-2 inhibitors), polyethylene glycol and removing free radical antioxidate and liquid |
| 07/28/2004 | CN1516576A Solid orally-dispersible pharmaceutical formulation |
| 07/28/2004 | CN1516553A Taste modifiers comprising chlorogenic acid |
| 07/28/2004 | CN1515590A Erythropoietin conjugate |
| 07/28/2004 | CN1515320A Colouring application of pearly pigment in medicine |
| 07/28/2004 | CN1515319A Induction of cytotoxic T lymphocyte response |
| 07/28/2004 | CN1515261A Topical medicine composite containing cholinergic drug or calcium channel paralyser |
| 07/28/2004 | CN1515260A Cinnarizine powder injection containing HPCD, its solid preparation and preparation method |
| 07/28/2004 | CN1515257A Paroxetine control-released composite |
| 07/28/2004 | CN1515247A Paint film based on dextrin and its composite |
| 07/28/2004 | CN1515244A Protein-stable pharmacological active matter, its preparation and application method |
| 07/28/2004 | CN1159421C Low temperature production process of matrix for sea-buckthorn medicine |
| 07/28/2004 | CN1159341C Method of treatment of corticosteroid induced osteopenia |
| 07/28/2004 | CN1159070C Preparation of high molecular gel stick agent |
| 07/28/2004 | CN1159062C Pharmaceutical compositions of peptides having low solubility in physiological medium |
| 07/28/2004 | CN1159012C Pharmaceutical composition of combination of piperidinoalkanol-decongestant |
| 07/28/2004 | CN1159002C Preparations for percutaneous absorption |
| 07/28/2004 | CN1159000C Buccal delivery system |
| 07/28/2004 | CN1158996C Medicinal aerosol formulations |
| 07/28/2004 | CN1158994C Topcial suspension formulations containing cirporfloxacin and dexa methasone |
| 07/28/2004 | CN1158993C Thermal stabilized antiacid and deaired suspensoid agent |
| 07/28/2004 | CN1158992C Microcrystalline cellulose/alginate pharmaceutical suspensions |
| 07/27/2004 | US6767924 Method of using hydroxycarboxylic acids or related compounds for treating skin changes associated with intrinsic and extrinsic aging |
| 07/27/2004 | US6767919 High specificity anticancer agents |
| 07/27/2004 | US6767917 Diuretics; cardiovascular, kidney and brain disorder treatment; antitumor, antiallergen, and antiasthmatic agents |
| 07/27/2004 | US6767901 Ciclesonide contained pharmaceutical composition for application to mucosa |
| 07/27/2004 | US6767894 Use of ciliary neurotrophic factor |
| 07/27/2004 | US6767892 Insulin-like growth factor-1 is solubilized with guanidinium compound |
| 07/27/2004 | US6767708 Stabilized aqueous steroid immunoassay standards |
| 07/27/2004 | US6767704 Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expression |
| 07/27/2004 | US6767635 Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| 07/27/2004 | US6767565 Recovering lignans from plants; obtain plant biomass, expose to extraction solvent, separate solid plant material, remove microorganism from extraction solution, recover lignan |
| 07/27/2004 | US6767559 DASC compositions, process for preparing same and suspensions containing same |
| 07/27/2004 | US6767558 Adding to a pharmaceutical formulation susceptible to oxidation, an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of an excipient |
| 07/27/2004 | US6767557 Taste masked pharmaceutical compositions |
| 07/27/2004 | US6767555 A cyclosporin-containing composition in the form of a capsule consists of a polyoxyethylene sorbitan fatty acid ester, a reaction product of a natural or hydrogenated castor oil, ethylene oxide, a sorbitan fatty ester, and ethanol |
| 07/27/2004 | US6767554 Use of complexes among cationic liposomes and polydeoxyribonucleotides and medicaments |
| 07/27/2004 | CA2069900C Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| 07/27/2004 | CA2056371C Stable microbubbles suspensions injectable into living organisms |
| 07/22/2004 | WO2004061458A2 Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| 07/22/2004 | WO2004061433A1 Pharmaceutical compositions with improved dissolution |
| 07/22/2004 | WO2004061043A1 Spraying composition |
| 07/22/2004 | WO2004060977A1 Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles |
| 07/22/2004 | WO2004060968A1 Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses |
| 07/22/2004 | WO2004060967A1 Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof |
| 07/22/2004 | WO2004060966A2 Maleamic acid polymer derivatives and their bioconjugates |
| 07/22/2004 | WO2004060965A2 Hydrolytically stable maleimide-terminated polymers |
| 07/22/2004 | WO2004060920A1 Complexes of protein crystals and ionic polymers |
| 07/22/2004 | WO2004060899A1 Phospholipid derivatives and process for the production there |
| 07/22/2004 | WO2004060791A1 Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| 07/22/2004 | WO2004060407A1 Calcium phosphate ceramics and particles for in vivo and in vitro transfection |
| 07/22/2004 | WO2004060406A2 Polymeric reagents comprising a ketone or a related functional group |
| 07/22/2004 | WO2004060405A2 Tissue reactive compounds and compositions and uses thereof |
| 07/22/2004 | WO2004060404A1 Drug carrier |
| 07/22/2004 | WO2004060403A2 Aprotinin and anglos as carriers across the blood-brain barrier |
| 07/22/2004 | WO2004060396A2 Immunogenic compositions containing phospholpid |
| 07/22/2004 | WO2004060386A1 Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein |
| 07/22/2004 | WO2004060384A2 Pharmaceutical botulinum toxin compositions |
| 07/22/2004 | WO2004060378A2 Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof |
| 07/22/2004 | WO2004060364A1 Skin lightening composition |
| 07/22/2004 | WO2004060357A1 Acid labile drug compositions |
| 07/22/2004 | WO2004060348A2 Ophthalmic and ophthalmological use of a complex nutritive base in an aqueous medium |
| 07/22/2004 | WO2004060347A2 Pharmaceutical propylene glycol solvate compositions |
| 07/22/2004 | WO2004060346A2 Drug delivery from rapid gelling polymer composition |
| 07/22/2004 | WO2004060345A2 Dispersible pharmaceutical compositions |
| 07/22/2004 | WO2004060342A1 Nutritional supplement composition and method |
| 07/22/2004 | WO2004060315A2 Stable topical drug delivery compositions |
| 07/22/2004 | WO2004060303A2 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 07/22/2004 | WO2004060300A2 Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| 07/22/2004 | WO2004060299A2 Polymer conjugates of interferon-beta with enhanced biological potency |
| 07/22/2004 | WO2004060268A2 A method and article to control cellulite |
| 07/22/2004 | WO2004060265A2 Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 07/22/2004 | WO2004060262A2 Modulators of notch signalling for use in immunotherpapy |
| 07/22/2004 | WO2004060041A2 Kim-1 antagonists and use to modulate immune system |
| 07/22/2004 | WO2004039817A9 Cardiolipin molecules and method of synthesis |
| 07/22/2004 | WO2004039411A3 Solid and semi-solid polymeric ionic conjugates |
| 07/22/2004 | WO2004039410A3 Liquid conjugates of solid pharmaceuticals |
| 07/22/2004 | WO2004037187A8 Metal-containing materials, compositions and methods |
| 07/22/2004 | WO2004022029A3 Branched alcohol-based personal care compositions |
| 07/22/2004 | WO2004019860A3 Formulations of modified antibodies and methods of making the same |
| 07/22/2004 | WO2004014951A3 Binding molecules |
| 07/22/2004 | WO2003106382A3 Reversed liquid crystalline phases with non-paraffin hydrophobes |
| 07/22/2004 | WO2003051398A8 Parenteral composition of paracetamol |
| 07/22/2004 | WO2003022869A3 Human immunodeficiency virus envelope clycoprotein mutants and uses thereof |
| 07/22/2004 | US20040143329 compressive modulus of elasticity of 0.1 - 10 megapascals, and a glass transition temperature greater than 40 degrees C.; especially for tissue replacement, tissue scaffolding or a low bearing surface within a joint |
| 07/22/2004 | US20040143005 Colon cleansing compositions and methods |
| 07/22/2004 | US20040142972 Sleep disorders; side effect reduction ; antihistamine antagonist |
| 07/22/2004 | US20040142911 acetone, a salicylate-based compound, an emollient and one or more terpenes and essential oils; treating pain associated with cancer |
| 07/22/2004 | US20040142900 polypeptide with the transport function of herpesviral VP22 protein and which can regulate cell cycle progression, e.g. proteins which can induce apoptosis, or proteins which can arrest cells from the cell cycle to arrest cell proliferation |
| 07/22/2004 | US20040142899 Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| 07/22/2004 | US20040142885 host cell; gene therapy |